Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3933166 | 0.86 | CFTR (0.66) | CFTR | |
| SCHEMBL8702211 | 0.83 | NR1D1 (0.59) | CFTRNR1D1 | |
| SCHEMBL8702216 | 0.83 | NR1D1 (0.59) | CFTRNR1D1 | |
| SCHEMBL29409298 | 0.82 | NR1D1 (0.62) | CFTRNR1D1 | |
| SCHEMBL28550513 | 0.82 | NR1D1 (0.62) | CFTRNR1D1 | |
| SCHEMBL3927560 | 0.82 | CFTR (0.68) | CFTR | |
| SCHEMBL3927567 | 0.82 | CFTR (0.68) | CFTR | |
| SCHEMBL28912058 | 0.81 | NR1D1 (0.61) | CFTRNR1D1 | |
| SCHEMBL29409308 | 0.81 | NR1D1 (0.61) | CFTRNR1D1 | |
| SCHEMBL16888938 | 0.80 | NR1D1 (0.61) | NR1D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541466-B2 | Tetrahydroisoquinoline derivatives for treating protein trafficking diseases | GENZYME CORPORATION (US) | 2009-06-02 | — | — | US | disclosed |
| US-20050176761-A1 | Tetrahydroisoquinoline derivatives for treating protein trafficking diseases | GENZYME CORPORATION (US) | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176761-A1 | Tetrahydroisoquinoline derivatives for treating protein trafficking diseases | CFTR, NPC1L1, GOLT1B | CFTR 1/4885NR1D1 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.